Literature DB >> 1877654

Effects of acute nitric oxide inhibition on rat glomerular microcirculation.

R Zatz1, G de Nucci.   

Abstract

Endothelium-derived relaxing factor (EDRF), recently identified as nitric oxide (NO), has been shown to be released by glomerular endothelial cells and might influence the glomerular microcirculation. To examine this hypothesis, we studied in rats the renal effect of acute administration of NG-monomethyl-L-arginine (L-NMMA), a specific inhibitor of NO synthesis. Adult male Munich-Wistar rats were studied before and after intravenous administration of either pure saline or a bolus injection of L-NMMA (20 mg) followed by a continuous infusion of the inhibitor (0.4 mg/min). Although saline alone had no effect on systemic or glomerular hemodynamics, L-NMMA promoted marked systemic hypertension, glomerular arteriolar vasoconstriction, and glomerular hypoperfusion. Since efferent resistance was disproportionately increased, glomerular hydraulic pressure was also markedly elevated. The glomerular ultrafiltration coefficient (Kf) fell to 42% of control. Single-nephron glomerular filtration rate was unaffected. Striking polyuria was also observed. These findings suggest that EDRF exerts a basal relaxing effect on the glomerular microcirculation.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1877654     DOI: 10.1152/ajprenal.1991.261.2.F360

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  27 in total

1.  Contribution of the renin-angiotensin system to short-term blood pressure variability during blockade of nitric oxide synthesis in the rat.

Authors:  O Gouédard; J Blanc; E Gaudet; P Ponchon; J L Elghozi
Journal:  Br J Pharmacol       Date:  1996-11       Impact factor: 8.739

2.  Endothelial nitric oxide synthase gene intron 4 a/b VNTR polymorphism in children with APSGN.

Authors:  Hasan Dursun; Aytul Noyan; Selcuk Matyar; Mithat Buyukcelik; Mustafa Soran; Nurcan Cengiz; Gulsah Seydaoglu; Gulen Attila; Aysun K Bayazit; Ali Anarat
Journal:  Pediatr Nephrol       Date:  2006-08-29       Impact factor: 3.714

Review 3.  Smooth muscle contractile diversity in the control of regional circulations.

Authors:  John J Reho; Xiaoxu Zheng; Steven A Fisher
Journal:  Am J Physiol Heart Circ Physiol       Date:  2013-11-01       Impact factor: 4.733

4.  Acute blockade of nitric oxide synthase inhibits renal vasodilation and hyperfiltration during pregnancy in chronically instrumented conscious rats.

Authors:  L A Danielson; K P Conrad
Journal:  J Clin Invest       Date:  1995-07       Impact factor: 14.808

Review 5.  Chronic nitric oxide inhibition model six years on.

Authors:  R Zatz; C Baylis
Journal:  Hypertension       Date:  1998-12       Impact factor: 10.190

6.  Angiotensin II subtype AT1 receptor blockade prevents hypertension and renal insufficiency induced by chronic NO-synthase inhibition in rats.

Authors:  M Hropot; K H Langer; Gabriele Wiemer; H Grötsch; W Linz
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-01-25       Impact factor: 3.000

7.  Support of renal blood flow after ischaemic-reperfusion injury by endogenous formation of nitric oxide and of cyclo-oxygenase vasodilator metabolites.

Authors:  J P Cristol; C Thiemermann; J A Mitchell; C Walder; J R Vane
Journal:  Br J Pharmacol       Date:  1993-05       Impact factor: 8.739

8.  Intrarenal haemodynamic and glomerular responses to inhibition of nitric oxide formation in rabbits.

Authors:  K M Denton; W P Anderson
Journal:  J Physiol       Date:  1994-02-15       Impact factor: 5.182

9.  Expression of nitric oxide synthase in macula densa in streptozotocin diabetic rats.

Authors:  N Yagihashi; N Nishida; H G Seo; N Taniguchi; S Yagihashi
Journal:  Diabetologia       Date:  1996-07       Impact factor: 10.122

10.  Endothelium-derived relaxing factor/nitric oxide modulates angiotensin II action in the isolated microperfused rabbit afferent but not efferent arteriole.

Authors:  S Ito; S Arima; Y L Ren; L A Juncos; O A Carretero
Journal:  J Clin Invest       Date:  1993-05       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.